Invion Limited (ASX:IVX)
Share Pricing & News Healthcare

AUD 0.0125

0 (0%)
(As on 2022-09-27 11:36:29 AEDT)
Previous Close Open Close*
0.0125 0.013 0.0125
Market Cap Dividend Yield (Annualized)
AUD 80.251M 0.00%

Day Range
0.0125L 0.013 H
52 WEEK HIGH LOW
0.008L 0.034 H

Chart Price & Information

Last Trade 0.0125
Change% 0.0000
52 W H/L 0.034/0.008
EBITDA -1.454M
NPAT After Abnormal Items -1.483M
Equity 4.791M
ROE% -30.96%
Total Liabilities 851,496
Total Revenue 2.419M
Cash and Cash Equivalents 1.037M

Stock Information

Share price 0.0125
Market Cap 80.251M
Price/Gross Cash Flow -94.72
Dividend Yield Excluding Special 0.00%
Ending Shares 5.54B
52-Week Range 0.034-0.008
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.00
P/E ratio 0.000
Sector P/E --
EPS -0.03
EV/EBITDA --
Net Profit Margin (%) -63.65%
Gross Cash Flows Per Share -0.00
Net Gearing -21.64%
Sales Per Share 0.00
Book Value Per Share 0.00

Similar Companies

Related Articles

About Company

Australian life sciences firm Invion Limited (ASX:IVX) is focused on transforming Photodynamic Therapy (PDT) to develop pioneering and effective cancer therapies.

PDT is an established treatment that enhances the utilisation of non-toxic photosensitisers as well as visible light for destroying cancer cells and invigorating the immune system. Invion is engaged in developing more effective, next-generation PDT that overcomes the multiple shortcomings of the existing PDT therapies.

Invion is a global leader in the R&D of Photosoft™ technology. The Company has the license as well as distribution rights to the Photosoft™ technology in Australia and New Zealand.

IVX has developed a new intravenous (IV) and topically administered product appropriate for solid tumours (prostate, ovarian, and lung cancer) and skin cancer.

Invion has signed an agreement with RMW Cho Group Limited for the clinical development of PhotosoftTM technology across the globe. RMW Cho also offers non-dilutive funding to Invion for the research and clinical trials of the PhotosoftTM Technology through an R&D services agreement.

The Company has partnered with world-leading medical research institutes for developing a novel photosensitiser named IVX-PDT. Invion is confident that this novel photosensitiser will improve the treatment of challenging solid cancers and skin cancers. The objective of developing IVX-PDT is to be more efficient in targeting and destroying cancer cells with no harmful side effects and negligible discomfort.

With a substantial clinical and commercial potential of its assets, Invion is advancing multiple programs and initiate pre-clinical and clinical studies in partnership with Hudson Institute of Medical Research and The Peter MacCallum Cancer Centre.

IVX and its research partners are targeting cancers, including topical indications for Actinic Keratosis and Basal Cell Carcinoma as well as intravenous indications for mesothelioma, rare cancer associated with asbestos exposure.

Corporate Information


Level 4, 100 Albert Road, SOUTH MELBOURNE, VIC, AUSTRALIA, 3205

Phone:+61 3 9692 7222

Email:investor@inviongroup.com

Website:http://www.inviongroup.com

Dividends

Ex-Date Net Dividend Frank Flag Period End Date Type Payable

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2023-08-17 2023
Report (Prelim) 2023-08-17 2023
Report (Interim) 2023-02-21 2023
AGM 2022-11-08 2022